Understanding infectious diseases through a systems biology approach
Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach
NA · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · NCT05557539
This study is trying to gather and analyze biological data from patients with COVID-19 to better understand why some people respond differently to the virus and improve their treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 275 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain (other) |
| Locations | 1 site (Brussels) |
| Trial ID | NCT05557539 on ClinicalTrials.gov |
What this trial studies
This study aims to collect extensive biological data from patients infected with SARS-CoV-2 and analyze it using a systems biology approach. It consists of two parts: the first part involves prospective sampling of patients during acute infection and convalescence, while the second part utilizes previously collected samples from another study. The goal is to identify key biological determinants that contribute to different responses to SARS-CoV-2, ultimately enhancing patient management through precision medicine.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and over with confirmed symptomatic SARS-CoV-2 infection or those presenting with hypoxemic respiratory failure from infectious causes.
Not a fit: Patients who are asymptomatic or those with acute respiratory infections unrelated to SARS-CoV-2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients with SARS-CoV-2 and influenza infections.
How similar studies have performed: Other studies utilizing systems biology approaches have shown promise in understanding infectious diseases, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or over * Patient or legal representative have provided informed consent * Cases: Reverse-transcriptase polymerase chain reaction (RT-PCR) confirmed symptomatic SARS-CoV-2 infection. * Controls : (1) Patient presenting with hypoxemic respiratory failure diagnosed by the treating physician as being from infectious origin; (2) SARS-CoV-2 infection excluded by RT-PCR and deemed non-probable by the treating physician. * Healthy controls : Patients presenting without acute respiratory failure (ie. SpO2 \>93%); (2) no RT-PCR or antigen rapid test proven SARS-CoV-2 infection within the last 6 months; (3) no active respiratory tract infection. Exclusion Criteria: * For all: (1) \<18 years old ; (2)unwilling to provide informed consent; (3) pregnancy at the time of inclusion * For cases: Asymptomatic infection * For controls: COVID-19 diagnosed by RT-PCR or suspect according to the treating physician at the time of inclusion, * For health controls: Acute or chronic respiratory failure.
Where this trial is running
Brussels
- Cliniques Universitaires Saint-Luc — Brussels, Belgium (RECRUITING)
Study contacts
- Principal investigator: Jean Cyr Yombi, MD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Jean Cyr Yombi, MD
- Email: jean.yombi@saintluc.uclouvain.be
- Phone: 003227642190
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: SARS-CoV-2 Infection, Influenza Viral Infections